Literature DB >> 1881464

Action of the racemate and the isomers of the platelet-activating factor antagonist bepafant (WEB 2170) after oral administration to guinea-pigs and rats.

H O Heuer1, B Keller, K Urich.   

Abstract

The aim of the present study was to clarify whether there is a difference in terms of potency and pharmacodynamic half time between the isomers and the racemate of the platelet-activating factor antagonist WEB 2170 (bepafant) after oral administration to guinea-pigs or rats. The following experiments were performed in the guinea-pig. Infusion of platelet-activating factor at 30 ng/(kg x min) for 30 min to anaesthetized guinea-pigs induced a decrease of respiratory flow and mean arterial blood pressure. Oral pretreatment with WEB 2170 or isomers, respectively, 60 min before infusion of platelet-activating factor inhibited these changes in a dose-dependent manner. The ED50s for inhibition of respiratory flow were: (-) WEB 2170 = 0.018 (0.009-0.036) mg/kg p.o; (+/-) WEB 2170 = 0.021 (0.015-0.03) mg/kg p.o.; (+) WEB 2170 = 1.55 (1.01-3.05) mg/kg p.o. Similar ED50 values were obtained for inhibition of decrease of MAP. Doses of isomers and racemate of WEB 2170 that provided almost complete protection against platelet-activating factor at 1 h after administration were chosen for determination of the duration of the protective effect after oral administration. Oral (-) WEB 2170 or (+/-) WEB 2170 showed almost identical time-response curves for inhibition (t1/2 = 14-17 h; 0.1 mg/kg p.o.) in the guinea-pig, whereas the duration of action of (+) WEB 2170 (3-6 h; 8 mg/kg) was significantly shorter. The following experiments were conducted in the rat. Oral pretreatment with WEB 2170 racemate and isomers resulted in a dose-dependent reversal of platelet-activating factor-induced hypotension.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1881464     DOI: 10.1007/bf00169560

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  5 in total

1.  Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.

Authors:  H O Heuer; J Casals-Stenzel; G Muacevic; K H Weber
Journal:  J Pharmacol Exp Ther       Date:  1990-12       Impact factor: 4.030

2.  Hypotensive activity of PAF-acether in rats.

Authors:  C G Caillard; S Mondot; J L Zundel; L Julou
Journal:  Agents Actions       Date:  1982-12

3.  Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives.

Authors:  B B Vargaftig; J Lefort; M Chignard; J Benveniste
Journal:  Eur J Pharmacol       Date:  1980-07-25       Impact factor: 4.432

4.  Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: evidence for a platelet independent mechanism.

Authors:  M Sánchez-Crespo; F Alonso; P Iñarrea; V Alvarez; J Egido
Journal:  Immunopharmacology       Date:  1982-04

5.  Studies on the hypotensive effects of platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) in rats, guinea pigs, rabbits, and dogs.

Authors:  S Tanaka; Y Kasuya; Y Masuda; K Shigenobu
Journal:  J Pharmacobiodyn       Date:  1983-11
  5 in total
  2 in total

Review 1.  Platelet-activating factor antagonists.

Authors:  M Koltai; P G Braquet
Journal:  Clin Rev Allergy       Date:  1994

2.  5-oxo-ETE induces pulmonary eosinophilia in an integrin-dependent manner in Brown Norway rats.

Authors:  P Stamatiou; Q Hamid; R Taha; W Yu; T B Issekutz; J Rokach; S P Khanapure; W S Powell
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.